Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-T Consolidation in B-ALL
NCT07072494Phase 2Recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Jul 2025
- Primary completion
- Mar 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD19 CAR-T cells in B-cell acute lymphoblastic leukemia (B-ALL), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: Leukemia-Free Survival at 12 months. Started Jul 2025; status: recruiting.
02
Drugs
CD19 CAR-T cells
03
Conditions
B-cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07072494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07072494.